Summary & Overview
HCPCS J9296: Pemetrexed (accord) Injection, 10 mg
HCPCS Level II code J9296 designates a 10 mg injection of pemetrexed (accord), identified as not therapeutically equivalent to J9305. This HCPCS code is used to bill a specific antineoplastic injectable formulation and matters nationally because pemetrexed is a widely used chemotherapy agent in several cancer indications; precise coding supports accurate provider reimbursement, inventory tracking, and payer utilization review.
Key payers covered in this publication include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find benchmarks for coding and billing practices, an overview of payer coverage considerations, and the clinical context for pemetrexed administration. The report outlines typical sites of service — infusion centers, outpatient hospital clinics, and physician offices — and highlights distinctions between J9296 and other pemetrexed codes where therapeutically relevant.
This summary provides guidance on what to expect in payer interactions and billing workflows, addresses common modifier usage patterns (listed separately), and notes when data elements are not provided. Data not available in the input will be identified explicitly in relevant sections.
Billing Code Overview
HCPCS Level II code J9296 represents an injection formulation of pemetrexed (accord), supplied in a 10 mg unit. The description specifies that this product is not therapeutically equivalent to J9305, indicating a distinct billing classification for this specific pemetrexed presentation.
Service Type: Injection — Antineoplastic Agent
Typical Site of Service: Infusion center, outpatient hospital clinic, or physician office
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with non–small cell lung cancer (NSCLC) or malignant pleural mesothelioma receiving systemic chemotherapy in an outpatient oncology infusion clinic. The clinician prescribes pemetrexed (generic/accord) dosed per body surface area for treatment or maintenance therapy. The medication J9296 (pemetrexed, 10 mg unit) is retrieved from pharmacy, prepared under sterile conditions by the infusion pharmacy (USP <797>/<800> compliant), and administered intravenously via peripheral IV or implanted venous access device (e.g., port-a-cath) during a scheduled chemotherapy visit. Pre‑medication with folic acid, vitamin B12, and corticosteroids is documented per protocol and baseline labs (CBC, renal function, liver tests) are reviewed prior to administration. The clinical workflow includes order verification, medication compounding, patient consent and education, verification of dosing calculations, IV access and infusion setup, administration with monitoring for infusion reactions, post‑infusion documentation, and billing using J9296 units corresponding to the total milligrams administered.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier |